Lululemon Athletica Inc. (LULU) Forms $81.40 Double Top; Shorts at Genmark Diagnostics (GNMK) Raised By 2.98%

February 17, 2018 - By Marguerite Chambers

Genmark Diagnostics Incorporated (NASDAQ:GNMK) had an increase of 2.98% in short interest. GNMK’s SI was 8.02 million shares in February as released by FINRA. Its up 2.98% from 7.78 million shares previously. With 485,500 avg volume, 17 days are for Genmark Diagnostics Incorporated (NASDAQ:GNMK)’s short sellers to cover GNMK’s short positions. The SI to Genmark Diagnostics Incorporated’s float is 19.2%. The stock decreased 5.47% or $0.26 during the last trading session, reaching $4.49. About 276,611 shares traded. GenMark Diagnostics, Inc. (NASDAQ:GNMK) has risen 116.11% since February 17, 2017 and is uptrending. It has outperformed by 99.41% the S&P500.

Lululemon Athletica Inc. (LULU) formed double top with $87.10 target or 7.00% above today’s $81.40 share price. Lululemon Athletica Inc. (LULU) has $11.02B valuation. The stock increased 0.59% or $0.48 during the last trading session, reaching $81.4. About 1.55 million shares traded. Lululemon Athletica Inc. (NASDAQ:LULU) has declined 19.33% since February 17, 2017 and is downtrending. It has underperformed by 36.03% the S&P500.

Analysts await Lululemon Athletica Inc. (NASDAQ:LULU) to report earnings on April, 4. They expect $1.22 EPS, up 22.00% or $0.22 from last year’s $1 per share. LULU’s profit will be $165.16M for 16.68 P/E if the $1.22 EPS becomes a reality. After $0.56 actual EPS reported by Lululemon Athletica Inc. for the previous quarter, Wall Street now forecasts 117.86% EPS growth.

Among 40 analysts covering Lululemon Athletica Inc. (NASDAQ:LULU), 23 have Buy rating, 1 Sell and 16 Hold. Therefore 58% are positive. Lululemon Athletica Inc. had 180 analyst reports since August 18, 2015 according to SRatingsIntel. The firm has “Buy” rating by William Blair given on Tuesday, January 9. The firm has “Hold” rating by Wells Fargo given on Thursday, January 11. Zacks upgraded the shares of LULU in report on Monday, August 31 to “Sell” rating. The firm earned “Mkt Perform” rating on Monday, December 12 by FBR Capital. Stifel Nicolaus maintained it with “Hold” rating and $75.0 target in Thursday, December 7 report. The firm earned “Mkt Perform” rating on Thursday, December 10 by Bernstein. The stock has “Hold” rating by Jefferies on Thursday, September 8. The company was maintained on Friday, September 11 by Cowen & Co. The stock has “Outperform” rating by Telsey Advisory Group on Monday, August 15. The stock has “Hold” rating by Wells Fargo on Friday, June 2.

Investors sentiment increased to 1.2 in 2017 Q3. Its up 0.24, from 0.96 in 2017Q2. It is positive, as 29 investors sold Lululemon Athletica Inc. shares while 89 reduced holdings. 54 funds opened positions while 88 raised stakes. 105.19 million shares or 0.45% more from 104.73 million shares in 2017Q2 were reported. Renaissance Limited Liability Company holds 0.02% or 323,500 shares. Tiaa Cref Inv Mngmt Lc reported 0.05% in Lululemon Athletica Inc. (NASDAQ:LULU). Acadian Asset Management Ltd Liability reported 135 shares. Prudential Finance holds 392,118 shares. Employees Retirement Association Of Colorado invested in 0.01% or 18,688 shares. Westfield Mgmt Company Lp owns 10,500 shares or 0.01% of their US portfolio. Mitsubishi Ufj Tru Banking stated it has 212,262 shares. Vantage Lc invested 0.01% in Lululemon Athletica Inc. (NASDAQ:LULU). 100 are owned by Next Grp Inc Inc. Hsbc Hldg Public Limited stated it has 133,226 shares. Ubs Asset Mgmt Americas Inc has 0.02% invested in Lululemon Athletica Inc. (NASDAQ:LULU). Envestnet Asset Mgmt invested in 3,353 shares or 0% of the stock. Edge Wealth Mngmt Limited Company, a New York-based fund reported 140 shares. Select Equity Group L P holds 0.25% or 518,856 shares in its portfolio. Sib has invested 5.92% of its portfolio in Lululemon Athletica Inc. (NASDAQ:LULU).

Investors sentiment decreased to 1.88 in Q3 2017. Its down 2.12, from 4 in 2017Q2. It worsened, as 11 investors sold GenMark Diagnostics, Inc. shares while 15 reduced holdings. 11 funds opened positions while 38 raised stakes. 56.57 million shares or 46.84% less from 106.41 million shares in 2017Q2 were reported. Moreover, Cadian Mngmt Lp has 1.82% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK) for 4.03 million shares. Ghost Tree Cap Ltd Limited Liability Company holds 1.94% or 950,000 shares in its portfolio. Voya Investment Mngmt Ltd Liability Company stated it has 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Alliancebernstein Limited Partnership has invested 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Royal State Bank Of Canada holds 4,283 shares or 0% of its portfolio. Jpmorgan Chase invested 0.01% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Granite Partners Lc reported 85,083 shares or 0.05% of all its holdings. Bnp Paribas Arbitrage holds 5,452 shares. Ameritas Investment Prns reported 3,729 shares. Tower Research Capital Lc (Trc) accumulated 6,769 shares. Moreover, Needham Management Ltd Com has 0.14% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK) for 57,000 shares. Citadel Advisors Ltd Liability Corp holds 0% or 88,143 shares in its portfolio. Trexquant L P owns 0.04% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK) for 15,696 shares. Ubs Asset Management Americas has invested 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Great West Life Assurance Com Can stated it has 7,315 shares or 0% of all its holdings.

Among 6 analysts covering Genmark Diagnostics (NASDAQ:GNMK), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Genmark Diagnostics had 19 analyst reports since October 14, 2015 according to SRatingsIntel. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) has “Buy” rating given on Monday, August 7 by Canaccord Genuity. The firm earned “Buy” rating on Monday, June 12 by Needham. The firm has “Market Perform” rating given on Friday, November 3 by Raymond James. The rating was upgraded by Cowen & Co to “Outperform” on Friday, September 16. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) has “Buy” rating given on Wednesday, October 28 by Needham. The firm earned “Buy” rating on Friday, November 3 by Canaccord Genuity. Canaccord Genuity maintained GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Monday, October 30 with “Buy” rating. The firm has “Buy” rating by Needham given on Wednesday, August 2. Needham maintained GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Tuesday, January 24 with “Buy” rating. The rating was maintained by Needham on Wednesday, February 24 with “Buy”.

Since August 15, 2017, it had 0 insider purchases, and 11 selling transactions for $420,867 activity. $17,086 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) was sold by Stier Eric. The insider Gleeson Michael sold 1,933 shares worth $18,267. $4,017 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) was sold by Mitchell Brian Andrew. Shares for $759 were sold by Kayyem Jon Faiz. On Monday, August 21 the insider Williams Jennifer Anne sold $18,635. 8,311 GenMark Diagnostics, Inc. (NASDAQ:GNMK) shares with value of $78,539 were sold by MASSARANY HANY. Mendel Scott also sold $17,800 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Tuesday, August 15.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. The company has market cap of $246.03 million. The firm provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It currently has negative earnings. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>